MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Merck & Co Inc.

Gesloten

SectorGezondheidszorg

86.61 -0.51

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

85.39

Max

87.02

Belangrijke statistieken

By Trading Economics

Inkomsten

583M

3.7B

Verkoop

-1B

16B

K/W

Sectorgemiddelde

13.318

63.778

EPS

1.72

Dividendrendement

3.61

Winstmarge

23.963

Werknemers

73,000

EBITDA

1.3B

6.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+28.42% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.61%

2.39%

Volgende Winsten

24 apr 2025

Volgende dividenddatum

7 apr 2025

Volgende Ex Dividend datum

16 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-26B

227B

Vorige openingsprijs

87.12

Vorige sluitingsprijs

86.61

Nieuwssentiment

By Acuity

39%

61%

145 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Merck & Co Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 12:33 UTC

Winsten

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb 2025, 11:57 UTC

Winsten

Merck 4Q Sales Increase Results in Swing to Profit

24 mrt 2025, 05:00 UTC

Winsten
Acquisities, Fusies, Overnames

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mrt 2025, 19:42 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mrt 2025, 10:30 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb 2025, 12:00 UTC

Top Nieuws

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb 2025, 14:48 UTC

Winsten

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb 2025, 11:51 UTC

Winsten

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb 2025, 11:50 UTC

Winsten

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Januvia/Janumet Sales $487M >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Keytruda Sales Up 19% >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Keytruda Sales $7.84B >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck Sees FY Rev $64.1B-$65.6B >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Adj EPS $1.72 >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Net $3.74B >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4 feb 2025, 11:30 UTC

Winsten

Merck 4Q Winrevair Sales $200M >MRK

Peer Vergelijking

Prijswijziging

Merck & Co Inc. Prognose

Koersdoel

By TipRanks

28.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.88 USD  28.42%

Hoogste 138 USD

Laagste 95 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck & Co Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

17 ratings

11

Buy

6

Hold

0

Sell

Technische score

By Trading Central

87.08 / 93.84Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

145 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.